FEATURED
Harrow purchases US commercialization rights to Samsung Bioepis' biosimilar portfolio

Acquisition includes two major anti-VEGF therapies for retinal diseases: OPUVIZ and BYOOVIZ, generic equivalents to EYLEA and Lucentis, respectively.

Earn FREE CE 24/7 with Courses by Eyes On Eyecare

Explore premium-quality, bite-sized courses featuring leading experts like Cecelia Koetting, OD, FAAO, and Cory Lappin, OD, MS, FAAO, and continuing education covering topics from ocular rosacea treatments to retinal disease.

TRENDING
Research